John L. Berk MD
Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine
Graduate Faculty (Primary Mentor of Grad Students)
72 E. Concord Street | (617) 358-4774jberk@bu.edu
john.berk@bmc.org

Sections
Pulmonary, Allergy, Sleep & Critical Care Medicine
Centers
Pulmonary Center
Amyloidosis Center
Evans Center for Interdisciplinary Biomedical Research
Biography
Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.
Education
MD, Case Western Reserve University
Biology, BA, Wesleyan University
Publications
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Jan 13. PMID: 39804640.
Published on 11/17/2024Wixner J, Berk JL, Adams D, Polydefkis M, Conceição I, Attarian S, Gillmore JD, Dyck PJB, Folkvaljon F, Zhou W, Chen J, Viney NJ, Kwoh TJ, Coelho T, Waddington-Cruz M. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. Amyloid. 2025 Mar; 32(1):29-38. PMID: 39552152.
Published on 11/17/2024Folkvaljon F, Gertz M, Gillmore JD, Khella S, Masri A, Maurer MS, Cruz MW, Wixner J, Chen J, Reicher B, Kwoh J, Yarlas A, Berk JL. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. Muscle Nerve. 2025 Jan; 71(1):96-107. PMID: 39552102.
Published on 8/30/2024Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 02; 392(1):33-44. PMID: 39213194.
Published on 8/13/2024Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2024 Oct; 271(10):6655-6666. PMID: 39138650.
Published on 3/21/2024Luigetti M, Quan D, Berk JL, Conceição I, Misumi Y, Chao CC, Bender S, Aldinc E, Vest J, Adams D. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study. Neurol Ther. 2024 Jun; 13(3):625-639. PMID: 38512694.
Published on 2/6/2024Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, Di Carli M, Solomon SD, Chen C, Yureneva E, Vest J, Gillmore JD. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024 Feb; 26(2):397-410. PMID: 38321786.
Published on 12/11/2023Lau KHV, Prokaeva T, Zheng L, Doros G, Kaku MC, Spencer B, Berk J, Sanchorawala V. Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis. Amyloid. 2024 Jun; 31(2):150-152. PMID: 38073425.
Published on 12/7/2023Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, Solomon SD. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024 Aug; 30(8):973-980. PMID: 38065307.
Published on 10/26/2023Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 Oct 26; 389(17):1553-1565. PMID: 37888916.
Media Mentions
Published on 9/19/2024
What to Tell Your Family if You Have Hereditary ATTR Amyloidosis
Published on 9/13/2022
Patisiran beneficial in ATTR amyloidosis with cardiomyopathy
Published on 9/8/2022
Alnylam details anticipated results from heart disease drug trial`
Published on 8/3/2022
Alnylam’s stock soars by nearly 50 percent on trial results for heart drug
Published on 6/26/2021
Intellia, with first results, delivers a 'landmark' for CRISPR gene editing
Published on 6/26/2021
Published on 3/12/2021
Published on 9/22/2020
Trial Data Provide Proof-of-concept for CRX-1008 as Leptomeningeal FAP Treatment
Published on 8/27/2018
Eyeing Approval, Pfizer Touts Tafamidis Data but Omits Key Details
Published on 8/3/2018
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
View full list of 10 media mentions.